


Online Supplemental Figure 1. Study design. Double-blind part consisting of three 14-day cross-over treatment periods separated by 19-23 –day wash-out periods. Visits at day 1, 5 and 14 of each treatment period. Six-month open-label follow-up with visits at 1, 3 and 6 months.



TC = telephone contact

- 1 1 mg in the morning for first 2 weeks
- 2 14 -25 d after last study treatment intake
- 3 \pm 2 days
- 4 \pm 7 days